they recommend that skincare products targeting AD should be developed with a focus on maintaining the balance of healthy skin microbiome. Overall, board members were in agreement that maintaining microbial homeostasis is a crucial component of AD therapies. Currently, an AD management program that includes reducing pathogenic organisms, optimizing the re-population of the (healthy diversified) microbiome, and restoring the skin barrier is needed. As the microbiome plays a role in the prevention of AD and also in the active phase of the disease,39,50 a product displaying pre- and post-biotic activity may prove beneficial.
Given the biological properties of LRP-TSW and of the biomass of Vitreoscilla filiformis, its use in a LRP-TSW and APF emollient for treating AD warrants consideration as a new strategy for treating inflammatory skin conditions.52,53 This process combines the beneficial effects of an emollient containing the lysate of nonpathogenic bacteria Vitreoscilla filiformis, to target a significant factor in the pathogenesis of AD. LRP-TSW displays anti-free radical, immunomodulatory, anti-inflammatory properties. It also introduces selenium and strontium to reduce the production of inflammatory cytokines.53 Furthermore, the biomass contained in the LRP-TSW and APF emollient releases lysates that normalize dysbiosis, re-balancing the bacterial content of lesions and nonlesional areas of AD skin.55 Given these findings, investigators approved of the use of this selenium-rich TSW as an active ingredient in topical, irritant-reducing formulations.53 Overall, these findings suggest that a new strategy for managing inflammatory skin diseases may be to combine the use of pre- and post-biotics into a moisturizer. Such a treatment may help restore homeostasis of the skin, re-populate the diversity of the microbiome, encourage the growth of commensal bacteria, and improve barrier function and symptoms of AD.
Funding: This review was supported by an unrestricted educational grant from La Roche-Posay Dermatological Laboratories, USA.
2. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70(1):3-11.
3. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908.
4. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am. 2015;35(1):161-183.
5. Garg N, Silverberg JI. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):281-288.
6. Eichenfield LF, Ellis CN, Mancini AJ, Paller AS, Simpson EL. Atopic dermatitis: epidemiology and pathogenesis update. Semin Cutan Med Surg. 2012;31(3 Suppl):S3-S5.
7. Del Rosso JQ, Harper J, Kircik L, et al. Consensus recommendations on adjunctive topical management of atopic dermatitis. J Drugs Dermatol. 2018;17(10):1070-1076.
8. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729-747. 9. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.
10. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
11. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-2223.
12. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: Who cares? Who pays? Journal of the American Academy of Dermatology. 1993;28(5, Part 1):699-703.
13. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol. 1998;139(1):73-76.
14. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol. 1996;34(5 Pt 1):760-764.
15. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-1258.e1223.